US Stock Market Move | Pharmaceutical stocks extend gains; Astrazeneca PLC Sponsored ADR (AZN.US) rises over 6% after earnings.

On Friday, US pharmaceutical stocks extended their gains. Eli Lilly (LLY.US) rose over 4%, while Astrazeneca PLC Sponsored ADR (AZN.US) gapped up and, as of press time, was up over 6%, with a cumulative gain of over 15% in October. On the news front, Astrazeneca PLC Sponsored ADR released its third-quarter 2026 results. At constant exchange rates (CER), total revenue for the quarter grew 7% year-on-year to US$16.209 billion, product sales rose 5% to US$15.066 billion, and alliance revenue increased 36% to US$1.107 billion. Core earnings per share were US$2.79, up 19% year-on-year; reported earnings per share were US$2.02, up 26%. According to consensus estimates compiled by MarketBeat, the market had expected core earnings per share of US$2.60 and revenue of US$16.0 billion for the quarter, with actual results coming in about 7% and 1% above expectations, respectively. By segment, oncology continued to drive growth: revenue was US$7.765 billion, up 17% year-on-year, accounting for 48% of total revenue. Within that, Imfinzi grew 26% to US$1.990 billion, Enhertu (including alliance revenue) grew 35% to US$1.581 billion, and Tagrisso grew 12% to US$2.087 billion.